Media Center
Filter by:
August 16, 2023
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
June 05, 2023
Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
May 17, 2023
Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect
January 09, 2023
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
December 05, 2022
Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy
December 05, 2022
Ninerafaxstat to Provide Optimal Ventricular Energetics in HCM: IMPROVE-HCM
October 10, 2022
Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase
September 15, 2022
Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium
August 26, 2022
Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022
August 26, 2022
IMPROVE DiCE: A Phase 2a Trial Investigating Ninerafaxstat - A Novel Cardiac Mitotrope for the treatment of Diabetic Cardiomyopathy
August 22, 2022
Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022
March 22, 2022
Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect
March 10, 2022
Imbria Pharmaceuticals Strengthens Executive Leadership Team with New Appointments
July 19, 2021
Imbria Pharmaceuticals Announces initiation of enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the safety, tolerability, and efficacy of IMB-1018972 (IMB-101) in patients with non-obstructive hypertrophic cardiomyopathy
July 05, 2021